These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29870645)

  • 1. [Alemtuzumab therapy 2017].
    Biernacki T; Bencsik K; Sandi D; Vécsei L
    Ideggyogy Sz; 2017 Nov; 70(11-12):371-380. PubMed ID: 29870645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
    Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Change of therapeutic algorithm in sclerosis multiplex based on two case reports].
    Biernacki T; Bencsik K; Kincses ZT; Sandi D; Fricska-Nagy Z; Faragó P; Vécsei L
    Ideggyogy Sz; 2017 Nov; 70(11-12):381-387. PubMed ID: 29870646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
    Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
    Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
    J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
    Ruck T; Afzali AM; Lukat KF; Eveslage M; Gross CC; Pfeuffer S; Bittner S; Klotz L; Melzer N; Wiendl H; Meuth SG
    BMC Neurol; 2016 Mar; 16():34. PubMed ID: 26966029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
    J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].
    Klotz L; Meuth SG; Kieseier B; Wiendl H
    Nervenarzt; 2013 Aug; 84(8):984-94. PubMed ID: 23793409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current evaluation of alemtuzumab in multiple sclerosis.
    Coyle PK
    Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.